Inactive Instrument

Satsuma Pharmaceuticals, Inc. Stock

STSA

US80405P1075

Biotechnology & Medical Research

Chart Satsuma Pharmaceuticals, Inc.

Duration

Period

Style

Dynamic Chart

Latest news about Satsuma Pharmaceuticals, Inc.

Satsuma Pharmaceuticals, Inc. Receives Complete Response Letter from the U.S. Food and Drug Administration	Jan. 17	CI
Satsuma Pharmaceuticals, Inc.(NasdaqGM:STSA) dropped from NASDAQ Composite Index	23-06-09	CI
Satsuma Pharmaceuticals, Inc.(NasdaqGM:STSA) dropped from S&P TMI Index	23-06-09	CI
Insider Buy: Satsuma Pharmaceuticals	23-06-08	MT
Satsuma Pharmaceuticals, Inc. Announces CFO Changes	23-06-08	CI
Satsuma Pharmaceuticals, Inc. Announces CEO Changes	23-06-08	CI
Satsuma Pharmaceuticals, Inc. Announces Board Changes	23-06-08	CI
Shin Nippon Biomedical Laboratories, Ltd. completed the acquisition of the remaining 91.6% stake in Satsuma Pharmaceuticals, Inc. from a group of sellers.	23-06-07	CI
Satsuma Pharmaceuticals' New Drug Application for Migraine Treatment Accepted for FDA Review	23-05-18	MT
Satsuma Pharmaceuticals, Inc. Announces FDA Acceptance of 505(b)(2) New Drug Application for STS101	23-05-18	CI
Satsuma Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
North American Morning Briefing : Sentiment -3-	23-04-19	DJ
HC Wainwright Downgrades Satsuma Pharmaceuticals to Neutral From Buy	23-04-18	MT
Shin Nippon Biomedical to Make $30 Million Offer for US-based Satsuma Pharmaceuticals	23-04-18	MT
Sector Update: Health Care Stocks Higher Premarket Monday	23-04-17	MT

More news

Analyst Recommendations on Satsuma Pharmaceuticals, Inc.

HC Wainwright Downgrades Satsuma Pharmaceuticals to Neutral From Buy	23-04-18	MT
SVB Securities Downgrades Satsuma Pharmaceuticals to Market Perform From Outperform, Adjusts Price Target to $1 From $15	22-11-15	MT
SVB Securities Upgrades Satsuma Pharmaceuticals to Outperform From Market Perform, Adjusts Price Target to $15 From $5	22-10-10	MT
HC Wainwright Adjusts Price Target on Satsuma Pharmaceuticals to $18 From $15, Reiterates Buy Rating	22-09-21	MT
Ladenburg Thalmann Starts Satsuma Pharmaceuticals at Buy With $16 Price Target	22-08-31	MT

More recommendations

Press releases Satsuma Pharmaceuticals, Inc.

Satsuma Pharmaceuticals and SNBL Announce Three Abstracts on STS101 for the Acute Treatment of Migraine to be presented at the American Headache Society's 65th Annual Scientific Meeting	23-06-16	AQ
Satsuma Pharmaceuticals and SNBL Announce Three Abstracts on STS101 for the Acute Treatment of Migraine to be Presented at the American Headache Society’s 65th Annual Scientific Meeting	23-06-15	AQ
Satsuma Pharmaceuticals : Termination of Material Agreement - Form 8-K	23-06-08	PU
Satsuma Pharmaceuticals Announces FDA Acceptance of 505(b)(2) NDA for STS101, a Novel and Investigational Dihydroergotamine Nasal Powder Product for the Acute Treatment of Migraine	23-05-19	AQ
SATSUMA PHARMACEUTICALS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	23-05-18	AQ

More press releases

Managers and Directors - Satsuma Pharmaceuticals, Inc.

Managers	Title	Age	Since
Ryoichi Nagata CEO	Chief Executive Officer	65	23-06-07
Mic Iwashima COO	Chief Operating Officer	46	16-12-31
Detlef F. Albrecht CTO	Chief Tech/Sci/R&D Officer	63	17-06-30

Members of the board	Title	Age	Since
Ryoichi Nagata CEO	Chief Executive Officer	65	23-06-07
Shuichi Kanazashi BRD	Director/Board Member	64	23-06-07
Ken Takanashi BRD	Director/Board Member	59	16-05-31

More insiders

Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a therapeutic product for the acute treatment of migraine. The Company's product candidate, STS101, is a drug-device combination of a dry-powder formulation of dihydroergotamine mesylate (DHE), which is designed to self-administered with a pre-filled, single-use, nasal delivery device. STS101 also incorporates an improved 2nd-generation nasal delivery device. STS101 is specifically designed to deliver the clinical advantages of DHE while overcoming its shortcomings.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-3.10%	102B
REGENERON PHARMACEUTICALS, INC.	+2.11%	96.07B
ARGENX SE	-1.80%	21.66B
BIONTECH SE	-17.75%	20.77B
GENMAB A/S	-6.91%	18.53B
WUXI APPTEC CO., LTD.	-42.00%	16.91B
BEIGENE, LTD.	-28.19%	13.79B
NEUROCRINE BIOSCIENCES, INC.	+0.18%	13.33B
SAREPTA THERAPEUTICS, INC.	+19.90%	10.94B